FDA Advisory Committee on the Safety of Celecoxib, Naproxen and Ibuprofen

Posted by on July 22, 2018

On April 24th – April 25th, 2018 a joint meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Committee convened to review supplemental new drug application (sNDA) 0209998/S-050 for Pfizer Pharmaceuticals’ COX-2 inhibitor Celecoxib (Celebrex). Celebrex is an oral tablet that can be used as an analgesic and for swelling and inflammation.
Read More

FDA Advisory Committee in Favor of 2 mg dose and Opposed to 4 mg dose of Eli Lilly’s Baricitinib

Posted by on July 21, 2018

On April 23, 2018 a meeting of the Arthritis Advisory Committee took place to review new drug application (NDA) 207924 sponsored by Eli Lilly and Company. The new molecular entity, baricitinib, is a Janus associated kinase inhibitor proposed for the treatment of active rheumatoid arthritis in adults who have not had an appropriate response to
Read More

FDA Advisory Committee Unanimously in Favor of GW Pharmaceuticals’ Epidiolex

Posted by on July 20, 2018

On April 19th, 2018 the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) convened to review new drug application (NDA) 210365 for GW Pharmaceuticals’ novel seizure drug, Epidiolex (cannabidiol). Cannabidiol (CBD) is an oral solution indicated for seizures associated with Lennox-Gastuat syndrome (LGS) and Dravet syndrome (DS) in patients at least 2 years old. 
Read More

The Promise of Biosimilars

Posted by and on July 20, 2018

What is the role of biosimilars in the biologics market? How do they effect patients, providers…etc? What is their impact on innovation? As discussed in our previous post “Biosimilars Approval: Opportunities and Challenges,” Biosimilars are drug products that are “highly similar” to an FDA-approved biological product. As the contemporary cousin of the generic drug, biosimilars
Read More

Biosimilars Approval: Opportunities and Challenges

Posted by on June 14, 2018

What are biosimilars and what makes them different from generic medicines? Biosimilars (also called follow-on biologics) are biologics medicines that are “highly similar” to an FDA-approved biological product, known as a reference product. Unlike most small-molecule drugs, which are chemically synthesized with highly predictable structures and functions, biologics and biosimilars are pharmaceutical compounds synthesized or extracted
Read More

Managing Relationships: Identifying and Engaging Thought Leaders in Pharma and Biotech

Posted by on March 29, 2018

Who are Key Opinion Leaders and why they are important? Key Opinion Leaders (KOLs) are physicians and scientific experts that have an independent voice or strong impact earned from an established reputation in their field. These thought leaders are extremely useful to pharmaceutical, medical device and biotech companies, as they can play an important role
Read More

Demand for Experts When the Stakes are High – The Added Value of KOLs

Posted by on March 26, 2018

A Key Opinion Leader (KOL) is an individual who has achieved such a significant social or professional status in a certain community, such as doctors, researchers, lawyers, celebrities, etc., that their recommendations can impact the decision-making process of their peers. The benefits of engaging KOLs is apparent in almost every industry but has been particularly
Read More

FDA Advisory Committee Gives Amgen Green Light on New Indication for Blincyto®

Posted by on March 14, 2018

On March 7th, 2018 the Oncologic Drugs Advisory Committee (ODAC) gathered to discuss supplemental biologic license application (sBLA) 125557/S-013, for Blincyto ® (blinatumomab) injection for intravenous use via Amgen, Inc.  The panel discussed the proposed indication for the treatment of minimal residue disease-positive B-cell precursor acute lymphoblastic leukemia (MRD+ ALL).  Amgen’s blinatumomab was awarded breakthrough therapy
Read More

FDA Advisory Committee Supports New Ulcerative Colitis Indication for Xeljanz (Tofacitinib)

Posted by on March 13, 2018

On March 8th, 2018 the FDA Gastrointestinal Drugs Advisory Committee (GDAC) discussed the supplemental new drug application (sNDA) 203214 supplement 18, for XELJANZ (tofacitinib) 5 mg and 10 mg tablets, submitted by Pfizer Inc., for the treatment of adults with moderate to severely active ulcerative colitis (UC) who have had inadequate response, loss of response,
Read More

FDA Advisory Committee Denies Charleston Laboratories’ Hydexor

Posted by on February 20, 2018

On February 14th, 2018 a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) reviewed new drug application (NDA) 209257 for Charleston Laboratories’ novel pain drug, Hydexor. Hydexor is a fixed-dose combination oral tablet containing hydrocodone, acetaminophen, and promethazine for the treatment
Read More